UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Phase I and pharmacokinetics study of topotecan, a new topoisomerase I inhibitor

Annals of oncology, 1993-09, Vol.4 (8), p.673-678

1993

Volltextzugriff (PDF)

Phase I clinical and pharmacokinetic study of topotecan administered by a 24-hour continuous infusion

Journal of clinical oncology, 1995-07, Vol.13 (7), p.1768-1776

1995

Volltextzugriff (PDF)

Phase I trial with weekly EO9, a novel bioreductive alkylating indoloquinone, by the EORTC Early Clinical Study Group (ECSG)

Cancer chemotherapy and pharmacology, 2000-01, Vol.45 (1), p.85-88

2000

Volltextzugriff (PDF)

Phase I and Pharmacologic Study of the Novel Indoloquinone Bioreductive Alkylating Cytotoxic Drug E09

JNCI : Journal of the National Cancer Institute, 1994-06, Vol.86 (12), p.906-912

1994

Volltextzugriff (PDF)

Phase I and pharmacokinetic study of a novel mitomycin C analog KW-2149

Anti-cancer drugs, 1995-02, Vol.6 (1), p.53-63

1995

Volltextzugriff (PDF)

Minimal guidelines for the monitoring of early clinical trials (phase I–II) in Europe under CRC/EORTC/NCI joint agreement

European journal of cancer (1990), 1992-01, Vol.28 (6), p.1289-1292

1992

Volltextzugriff (PDF)

Replacement of cisplatin with carboplatin in combination chemotherapy against ovarian cancer: long-term treatment results of a study of the Gynaecological Cancer Cooperative Group of the EORTC and experience at The Netherlands Cancer Institute

Seminars in oncology, 1992-02, Vol.19 (1 Suppl 2), p.99

1992

Volltextzugriff (PDF)

Phase I and pharmacokinetic study of rhizoxin

Cancer research (Chicago, Ill.), 1992-05, Vol.52 (10), p.2894-2898

1992

Volltextzugriff (PDF)

Clinical studies with EO9, a new indoloquinone bioreductive alkylating cytotoxic agent. EORTC Early Clinical Trials Group

Oncology research, 1994, Vol.6 (10-11), p.519

1994

Volltextzugriff (PDF)

Phase I study on EO9 given every 3 weeks

European journal of cancer (1990), 1993, Vol.29, p.S117-S117

1993

Volltextzugriff (PDF)

A phase I and pharmacokinetic trial of KW-2149, a mitomycin C analogue, in patients with solid tumours

European journal of cancer (1990), 1993, Vol.29, p.S118-S118

1993

Volltextzugriff (PDF)

SDZ PSC 833 in combination with doxorubicin: a phase I and pharmacologic study in solid tumors

Anti-cancer drugs, 1994-09, Vol.5, p.42

1994

Volltextzugriff (PDF)

EORTC New Drug Development Office coordinating and monitoring programme for phase I and II trials with new anticancer agents

European journal of cancer (1990), 1991, Vol.27 (9), p.1162-1168

1991

Volltextzugriff (PDF)

SDZ PSC 833 in combination with doxorubicin: a phase I and pharmacologic study in solid tumors: 98

Anti-cancer drugs, 1994-09, Vol.5 Suppl 1, p.42-42

1994

Volltextzugriff (PDF)

EORTC new drug development office coordinating and monitoring programme for phase I and II trials with new anticancer agents

European journal of cancer & clinical oncology, 1991, Vol.27 (9), p.1162-1168

1991

Volltextzugriff (PDF)

How accurately does output reflect the nature and design of transdisciplinary research programmes?

Research evaluation, 2015-01, Vol.24 (1), p.37-50

2015

Volltextzugriff (PDF)

Phase I Clinical and Pharmacokinetic Study of Topotecan Administered by a 24-Hour Continuous Infusion

Journal of clinical oncology, 1996-02, Vol.14 (2), p.689

1996

Volltextzugriff (PDF)

Mitoxantrone and GM-CSF : a phase I study with an escalated dose of mitoxantrone in breast cancer

Pathologie biologie (Paris), 1991-11, Vol.39 (9)

1991

Volltextzugriff (PDF)

Mitoxantrone and GM-CSF: a phase I study with an escalated dose of mitoxantrone in breast cancer

Pathologie biologie (Paris), 1992-11, Vol.39 (9), p.962

1992

Volltextzugriff (PDF)

1 – 19 von 19

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(17)
Mit Volltextzugriff
(14)

Publikationsform

Artikel
(19)

Sprache

Englisch
(19)

Erscheinungsjahr

n.n

Menü

Weitere Dienste

Einstellungen

Phase I and pharmacokinetics study of topotecan, a new topoisomerase I inhibitor

Phase I clinical and pharmacokinetic study of topotecan administered by a 24-hour continuous infusion

Phase I trial with weekly EO9, a novel bioreductive alkylating indoloquinone, by the EORTC Early Clinical Study Group (ECSG)

Phase I and Pharmacologic Study of the Novel Indoloquinone Bioreductive Alkylating Cytotoxic Drug E09

Phase I and pharmacokinetic study of a novel mitomycin C analog KW-2149

Minimal guidelines for the monitoring of early clinical trials (phase I–II) in Europe under CRC/EORTC/NCI joint agreement

Replacement of cisplatin with carboplatin in combination chemotherapy against ovarian cancer: long-term treatment results of a study of the Gynaecological Cancer Cooperative Group of the EORTC and experience at The Netherlands Cancer Institute

Phase I and pharmacokinetic study of rhizoxin

Clinical studies with EO9, a new indoloquinone bioreductive alkylating cytotoxic agent. EORTC Early Clinical Trials Group

Phase I study on EO9 given every 3 weeks

A phase I and pharmacokinetic trial of KW-2149, a mitomycin C analogue, in patients with solid tumours

SDZ PSC 833 in combination with doxorubicin: a phase I and pharmacologic study in solid tumors

EORTC New Drug Development Office coordinating and monitoring programme for phase I and II trials with new anticancer agents

SDZ PSC 833 in combination with doxorubicin: a phase I and pharmacologic study in solid tumors: 98

EORTC new drug development office coordinating and monitoring programme for phase I and II trials with new anticancer agents

How accurately does output reflect the nature and design of transdisciplinary research programmes?

Phase I Clinical and Pharmacokinetic Study of Topotecan Administered by a 24-Hour Continuous Infusion

Mitoxantrone and GM-CSF : a phase I study with an escalated dose of mitoxantrone in breast cancer

Mitoxantrone and GM-CSF: a phase I study with an escalated dose of mitoxantrone in breast cancer

Suchergebnisse filtern